¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 14

PROSIGNA within HR+/HER2-neg and 1 positive node

•

TransATAC + ABCSG08 combined analysis

•

N=331 1N+ and 212 2-3N+

•

5-years of endocrine therapy and no chemotherapy

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,4,5,6,7,8,9,10,11,12,13 15,16,17,18,19,20,21,22,23,...24